Please check your internet connection and try again.
# Tirzepatide
## Overview
- **Classification**: Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
- **Mechanism**: Activates both GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing food intake.
## Primary Indications
1. **Type 2 Diabetes Mellitus (T2DM)** - Adjunct to diet and exercise to improve glycemic control.
2. **Chronic Weight Management (CWM)** - For adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity.
## Adult Dosing
### Standard Dosing
**Type 2 Diabetes Mellitus & Chronic Weight Management**
- **Initial Dose**: **2.5 mg** once weekly.
- **Frequency**: Once weekly.
- **Route**: Subcutaneous (SC) injection.
- **Titration**: Increase to **5 mg** once weekly after 4 weeks.
- **Further Titration**: May increase by **2.5 mg** increments after at least 4 weeks on the current dose.
- **Maintenance Doses**: **5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg** once weekly.
- **Maximum Dose**: **15 mg** once weekly.
- **Special Considerations**: Administer on the same day each week, any time of day, with or without food.
### Dose Adjustments
- **Renal Impairment**: No dose adjustment needed for any degree of renal impairment, including ESRD.
- **Hepatic Impairment**: No dose adjustment needed for any degree of hepatic impairment.
- **Elderly Patients**: No dose adjustment needed. Monitor for dehydration due to potential GI adverse effects.
## Pediatric Dosing
Tirzepatide is **not indicated** for pediatric patients (0-18 years).
- **Special Notes**: Safety and efficacy have not been established in this population. Do not use in pediatric patients.
## Safety Information
### Contraindications
- **Absolute**: Personal or family history of Medullary Thyroid Carcinoma (MTC).
- **Absolute**: Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- **Absolute**: Known serious hypersensitivity to tirzepatide or any excipient.
### Common Adverse Effects
- **Very Common (>10%)**: Nausea, Diarrhea, Vomiting, Constipation, Abdominal pain.
- **Common (1-10%)**: Dyspepsia, Injection site reactions, Fatigue, Hypoglycemia (with insulin/sulfonylurea).
- **Serious but Rare**: Pancreatitis, Hypoglycemia, Acute kidney injury, Gallbladder disease (cholelithiasis, cholecystitis), Thyroid C-cell tumors (based on rodent studies), Hypersensitivity reactions (angioedema, anaphylaxis).
### Key Drug Interactions
- **Oral Contraceptives**: May decrease efficacy due to delayed gastric emptying. Advise non-oral or barrier method for **4 weeks** after initiation and each dose escalation.
- **Drugs requiring rapid GI absorption**: Monitor closely as tirzepatide delays gastric emptying.
- **Insulin/Sulfonylureas**: Increased risk of hypoglycemia. May need to reduce dose of concomitant insulin or sulfonylurea.
## Monitoring & Follow-up
- **Before Treatment**: Assess personal/family history of MTC or MEN 2.
- **During Treatment**: Monitor for signs/symptoms of pancreatitis (persistent severe abdominal pain).
- **During Treatment**: Monitor blood glucose if on concomitant insulin or sulfonylurea.
- **Clinical Signs**: Watch for signs of dehydration (especially with severe GI upset) and symptoms of gallbladder disease.
## Clinical Pearls
- 💡 **Administration**: Inject SC in abdomen, thigh, or upper arm. Rotate injection sites.
- 💡 **Storage**: Refrigerate pens. Protect from light. Can be kept at room temperature (up to 30°C/86°F) for up to 21 days.
- 💡 **Not for T1DM**: Not a substitute for insulin. Not indicated for Type 1 Diabetes Mellitus.
- 💡 **Missed Dose**: If a dose is missed, administer as soon as possible within 4 days (96 hours). If more than 4 days, skip and administer the next dose on the regularly scheduled day.
- 💡 **Patient Counseling**: Counsel on managing GI side effects (e.g., smaller meals, bland foods, avoid fatty foods).
> **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.